These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30422005)

  • 21. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.
    Dellis A; Papatsoris AG
    Expert Opin Investig Drugs; 2016 Jun; 25(6):697-707. PubMed ID: 26954621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.
    Rycaj K; Cho EJ; Liu X; Chao HP; Liu B; Li Q; Devkota AK; Zhang D; Chen X; Moore J; Dalby KN; Tang DG
    Oncotarget; 2016 Mar; 7(12):14220-40. PubMed ID: 26871947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC).
    Boegemann M; Schrader AJ; Krabbe LM; Herrmann E
    Curr Cancer Drug Targets; 2015; 15(3):243-55. PubMed ID: 25654638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
    Fujimoto N
    Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
    Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
    Coutinho I; Day TK; Tilley WD; Selth LA
    Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Darolutamide (ODM-201) for the treatment of prostate cancer.
    Shore ND
    Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential of AR-V7 as a therapeutic target.
    Uo T; Plymate SR; Sprenger CC
    Expert Opin Ther Targets; 2018 Mar; 22(3):201-216. PubMed ID: 29417861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New agents for prostate cancer.
    Agarwal N; Di Lorenzo G; Sonpavde G; Bellmunt J
    Ann Oncol; 2014 Sep; 25(9):1700-1709. PubMed ID: 24658665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigational serine/threonine kinase inhibitors against prostate cancer metastases.
    Festuccia C
    Expert Opin Investig Drugs; 2017 Jan; 26(1):25-34. PubMed ID: 27892725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
    Galletti G; Leach BI; Lam L; Tagawa ST
    Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug therapies for metastatic castration-resistant prostate cancer.
    El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
    Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
    Rathkopf DE; Larson SM; Anand A; Morris MJ; Slovin SF; Shaffer DR; Heller G; Carver B; Rosen N; Scher HI
    Cancer; 2015 Nov; 121(21):3853-61. PubMed ID: 26178426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
    Virgo KS; Basch E; Loblaw DA; Oliver TK; Rumble RB; Carducci MA; Nordquist L; Taplin ME; Winquist E; Singer EA
    J Clin Oncol; 2017 Jun; 35(17):1952-1964. PubMed ID: 28441112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apalutamide for the treatment of prostate cancer.
    Rathkopf DE; Scher HI
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):823-836. PubMed ID: 30101644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.